Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma Pharmaceutical Investing
Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality Pharmaceutical Investing
Gossamer Bio Announces Presentations at the European Respiratory Society Congress 2025 Pharmaceutical Investing
ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business Model Pharmaceutical Investing
Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025 Pharmaceutical Investing
Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025 Pharmaceutical Investing
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation Pharmaceutical Investing
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update Pharmaceutical Investing
NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana Pharmaceutical Investing
Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Pharmaceutical Investing
Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto Psychedelics Investing
